Nifty
:
19664.70
Sensex
:
65945.47
-9.85 (-0.05%)
-78.22 (-0.12%)
Nifty
Sensex
:
:
19664.70
65945.47
-9.85 (-0.05%)
-78.22 (-0.12%)

JB Chemicals & Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
60/99

BSE: 506943 | NSE: JBCHEPHARM

NSE BSE
1407.15
26-Sep-2023
  • Open
  • High
  • Low
  • Previous Close
  •  1428.10
  •  1444.05
  •  1402.20
  •  1433.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  75416
  •  1065.35
  •  1524.50
  •  875.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 21,827.81
  • 48.82
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 22,297.23
  • 0.32%
  • 8.73

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.91%
  • 0.59%
  • 15.66%
  • FII
  • DII
  • Others
  • 9.53%
  • 18.12%
  • 2.19%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.91
  • 13.89
  • 15.53

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.72
  • 17.87
  • 4.58

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.89
  • 16.20
  • -2.92

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.10
  • 25.95
  • 31.17

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.87
  • 4.85
  • 6.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.52
  • 16.85
  • 21.06

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Net Sales
896.20
784.81
14.19%
762.32
624.59
22.05%
792.71
600.65
31.98%
809.44
593.01
36.50%
Expenses
664.09
612.05
8.50%
598.68
499.67
19.82%
617.94
472.55
30.77%
624.86
466.26
34.02%
EBITDA
232.11
172.76
34.35%
163.64
124.92
31.00%
174.77
128.10
36.43%
184.58
126.75
45.63%
EBIDTM
25.90%
22.01%
21.47%
20.00%
22.05%
21.33%
22.80%
21.37%
Other Income
5.63
0.89
532.58%
4.58
2.08
120.19%
3.13
4.53
-30.91%
1.34
19.65
-93.18%
Interest
12.06
5.83
106.86%
13.96
1.61
767.08%
8.30
1.34
519.40%
7.96
1.23
547.15%
Depreciation
31.38
26.08
20.32%
31.80
22.11
43.83%
28.40
16.97
67.35%
28.13
15.74
78.72%
PBT
194.30
141.74
37.08%
122.46
103.28
18.57%
141.20
114.32
23.51%
149.83
129.43
15.76%
Tax
51.98
36.54
42.26%
34.83
18.31
90.22%
35.10
30.21
16.19%
38.75
31.54
22.86%
PAT
142.32
105.20
35.29%
87.63
84.97
3.13%
106.10
84.11
26.14%
111.08
97.89
13.47%
PATM
15.88%
13.40%
11.50%
13.60%
13.38%
14.00%
13.72%
16.51%
EPS
9.19
6.79
35.35%
5.66
5.49
3.10%
6.86
5.43
26.34%
7.18
6.32
13.61%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
3,260.67
3,149.28
2,424.24
2,042.52
1,774.73
1,643.20
1,413.77
1,368.32
1,231.58
1,144.21
1,021.86
Net Sales Growth
25.26%
29.91%
18.69%
15.09%
8.00%
16.23%
3.32%
11.10%
7.64%
11.97%
 
Cost Of Goods Sold
1,185.39
1,168.20
842.93
701.50
630.80
596.46
542.41
552.00
491.41
341.40
413.95
Gross Profit
2,075.28
1,981.08
1,581.31
1,341.02
1,143.93
1,046.74
871.35
816.32
740.17
802.81
607.92
GP Margin
63.65%
62.91%
65.23%
65.66%
64.46%
63.70%
61.63%
59.66%
60.10%
70.16%
59.49%
Total Expenditure
2,505.57
2,453.53
1,881.63
1,486.35
1,397.15
1,337.36
1,214.64
1,135.93
1,025.55
964.09
873.67
Power & Fuel Cost
-
91.54
71.47
62.60
61.54
63.29
58.28
54.89
55.28
53.02
46.61
% Of Sales
-
2.91%
2.95%
3.06%
3.47%
3.85%
4.12%
4.01%
4.49%
4.63%
4.56%
Employee Cost
-
543.45
439.24
340.60
322.92
288.18
251.10
217.34
175.31
159.56
143.67
% Of Sales
-
17.26%
18.12%
16.68%
18.20%
17.54%
17.76%
15.88%
14.23%
13.94%
14.06%
Manufacturing Exp.
-
210.91
194.00
148.68
140.70
150.49
139.83
131.45
119.35
223.53
102.44
% Of Sales
-
6.70%
8.00%
7.28%
7.93%
9.16%
9.89%
9.61%
9.69%
19.54%
10.02%
General & Admin Exp.
-
110.09
100.46
56.35
48.14
52.97
53.96
42.26
34.82
32.46
31.69
% Of Sales
-
3.50%
4.14%
2.76%
2.71%
3.22%
3.82%
3.09%
2.83%
2.84%
3.10%
Selling & Distn. Exp.
-
233.96
161.80
113.22
116.95
113.59
87.44
78.27
72.72
75.13
73.59
% Of Sales
-
7.43%
6.67%
5.54%
6.59%
6.91%
6.18%
5.72%
5.90%
6.57%
7.20%
Miscellaneous Exp.
-
95.38
71.72
63.38
76.11
72.38
81.61
59.72
76.65
79.01
73.59
% Of Sales
-
3.03%
2.96%
3.10%
4.29%
4.40%
5.77%
4.36%
6.22%
6.91%
6.04%
EBITDA
755.10
695.75
542.61
556.17
377.58
305.84
199.13
232.39
206.03
180.12
148.19
EBITDA Margin
23.16%
22.09%
22.38%
27.23%
21.28%
18.61%
14.09%
16.98%
16.73%
15.74%
14.50%
Other Income
14.68
9.94
40.07
116.62
50.90
41.44
55.29
50.16
56.65
10.89
37.70
Interest
42.28
36.05
5.12
7.24
3.26
4.65
3.49
5.37
10.65
6.82
5.93
Depreciation
119.71
114.41
72.66
68.67
66.32
55.64
56.97
47.22
41.22
38.64
28.02
PBT
607.79
555.23
504.90
596.89
358.89
286.99
193.95
229.94
210.82
145.55
151.94
Tax
160.66
145.23
118.86
148.36
76.50
93.02
55.23
45.55
49.58
45.14
25.95
Tax Rate
26.43%
26.16%
23.54%
24.86%
21.93%
32.41%
28.48%
19.81%
23.52%
31.01%
29.68%
PAT
447.13
409.84
385.36
447.96
272.04
193.47
138.34
184.06
161.14
100.41
61.50
PAT before Minority Interest
447.13
410.01
386.04
448.52
272.39
193.97
138.72
184.40
161.24
100.41
61.50
Minority Interest
0.00
-0.17
-0.68
-0.56
-0.35
-0.50
-0.38
-0.34
-0.10
0.00
0.00
PAT Margin
13.71%
13.01%
15.90%
21.93%
15.33%
11.77%
9.79%
13.45%
13.08%
8.78%
6.02%
PAT Growth
20.14%
6.35%
-13.97%
64.67%
40.61%
39.85%
-24.84%
14.22%
60.48%
63.27%
 
EPS
57.77
52.95
49.79
57.88
35.15
25.00
17.87
23.78
20.82
12.97
7.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
2,480.35
2,134.12
1,809.72
1,435.49
1,480.12
1,441.56
1,363.67
1,183.84
994.87
1,042.81
Share Capital
15.48
15.46
15.46
15.46
16.05
16.71
16.96
16.96
16.96
16.95
Total Reserves
2,343.26
2,056.01
1,794.27
1,420.03
1,464.08
1,424.84
1,346.70
1,166.87
977.91
1,025.82
Non-Current Liabilities
992.03
475.34
72.47
62.72
64.84
45.66
26.98
31.02
32.62
31.93
Secured Loans
383.22
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.09
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.40
0.40
Long Term Provisions
494.68
410.43
12.57
7.39
5.73
9.67
12.56
10.43
12.03
12.19
Current Liabilities
625.70
455.16
686.57
516.19
781.54
736.50
693.46
797.22
459.75
276.27
Trade Payables
238.65
224.48
186.92
167.97
117.37
110.39
98.98
90.85
77.51
60.75
Other Current Liabilities
240.33
81.31
89.82
102.67
93.10
119.75
122.15
138.73
103.74
98.06
Short Term Borrowings
28.02
26.32
32.64
29.49
25.80
29.29
48.86
193.02
126.88
81.71
Short Term Provisions
118.71
123.06
377.17
216.06
545.27
477.06
423.47
374.61
151.62
35.76
Total Liabilities
4,098.08
3,069.11
2,572.47
2,016.90
2,329.30
2,226.49
2,086.29
2,013.75
1,487.24
1,351.01
Net Block
1,901.01
1,276.99
633.65
651.26
620.93
639.50
679.44
440.22
328.56
310.55
Gross Block
2,607.77
1,876.20
1,182.55
1,177.43
1,084.83
1,053.76
1,038.55
753.75
601.67
540.54
Accumulated Depreciation
706.76
599.21
548.90
526.17
463.89
414.25
359.10
313.53
273.11
229.99
Non Current Assets
2,498.80
1,744.51
678.57
740.83
740.80
717.89
879.15
831.58
586.31
370.37
Capital Work in Progress
55.15
18.68
25.57
16.17
15.09
17.40
3.76
134.89
55.17
46.36
Non Current Investment
13.78
12.72
12.91
69.45
95.88
49.96
185.84
231.42
184.83
2.75
Long Term Loans & Adv.
514.35
435.07
5.62
3.59
8.31
10.15
9.43
22.63
17.74
10.71
Other Non Current Assets
14.51
1.04
0.82
0.36
0.59
0.88
0.67
2.43
0.00
0.00
Current Assets
1,599.29
1,324.61
1,893.89
1,276.08
1,588.51
1,508.59
1,207.14
1,182.16
900.94
980.65
Current Investments
192.18
0.00
664.97
333.81
360.65
383.77
224.96
247.28
366.78
497.26
Inventories
430.48
409.96
347.45
274.67
243.76
213.73
200.17
187.98
150.27
134.40
Sundry Debtors
575.80
555.69
389.02
345.43
308.22
300.73
265.97
272.64
262.35
235.51
Cash & Bank
78.81
58.53
30.85
30.95
36.80
29.92
13.39
12.90
25.19
11.81
Other Current Assets
322.00
57.43
45.95
18.89
639.08
580.44
502.66
461.34
96.35
101.68
Short Term Loans & Adv.
277.09
243.00
415.66
272.33
605.85
567.50
488.30
458.83
95.97
101.48
Net Current Assets
973.58
869.45
1,207.33
759.88
806.97
772.10
513.68
384.94
441.19
704.37
Total Assets
4,098.09
3,069.12
2,572.46
2,016.91
2,329.31
2,226.48
2,086.29
2,013.74
1,487.25
1,351.02

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
625.61
170.13
314.78
275.75
194.33
122.92
201.13
140.41
126.66
-13.98
PBT
555.23
504.90
596.89
348.89
286.99
193.95
229.94
212.23
145.55
87.44
Adjustment
195.78
102.27
-46.17
7.95
23.72
16.91
13.11
-1.40
38.51
20.75
Changes in Working Capital
-29.92
-302.42
-94.21
9.70
-51.47
-47.07
5.92
-16.96
-19.52
-93.71
Cash after chg. in Working capital
721.09
304.75
456.50
366.55
259.24
163.79
248.97
193.88
164.53
14.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-95.48
-134.62
-141.72
-90.80
-64.91
-40.87
-47.84
-53.47
-37.87
-28.47
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-961.79
2.32
-230.68
23.93
-27.67
-20.68
-45.31
-27.62
-111.89
-142.50
Net Fixed Assets
-761.82
-681.80
-12.39
-94.42
-29.82
-29.56
-152.86
-187.76
-69.64
-55.43
Net Investments
-193.24
665.16
-274.62
53.26
-22.80
-22.92
67.89
-14.16
-61.38
-102.46
Others
-6.73
18.96
56.33
65.09
24.95
31.80
39.66
174.30
19.13
15.39
Cash from Financing Activity
356.54
-138.39
-87.42
-306.05
-155.74
-59.52
-183.84
-99.62
-1.39
12.04
Net Cash Inflow / Outflow
20.36
34.07
-3.31
-6.38
10.92
42.72
-28.02
13.17
13.38
-144.43
Opening Cash & Equivalents
56.54
22.47
25.75
32.14
21.24
-21.47
6.54
-5.46
11.81
156.23
Closing Cash & Equivalent
76.93
56.54
22.47
25.75
32.14
21.24
-21.47
9.42
25.19
11.81

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
152.42
134.02
234.17
185.75
184.47
172.50
160.77
139.57
117.31
123.07
ROA
11.44%
13.69%
19.55%
12.53%
8.52%
6.43%
8.99%
9.21%
7.08%
4.64%
ROE
18.51%
19.89%
27.64%
18.69%
13.28%
9.89%
14.48%
14.80%
9.86%
5.99%
ROCE
22.79%
25.48%
36.53%
23.71%
19.59%
13.70%
16.87%
17.72%
13.49%
8.50%
Fixed Asset Turnover
1.46
1.63
1.73
1.57
1.54
1.35
1.53
1.82
2.03
1.92
Receivable days
63.16
69.29
65.62
67.22
67.63
73.15
71.84
79.28
78.41
75.30
Inventory Days
46.91
55.55
55.59
53.31
50.81
53.43
51.77
50.12
44.83
42.16
Payable days
72.35
89.07
92.33
38.74
32.21
33.66
32.86
32.45
27.82
26.91
Cash Conversion Cycle
37.72
35.77
28.88
81.79
86.23
92.93
90.75
96.95
95.43
90.54
Total Debt/Equity
0.23
0.01
0.02
0.02
0.02
0.02
0.04
0.16
0.13
0.09
Interest Cover
16.40
99.60
83.43
108.09
62.74
56.54
43.81
20.80
22.33
15.74

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • JB Chemicals & Pharmaceuticals gets USFDA’s nod for Doxepin Hydrochloride Capsules
    23rd Aug 2023, 14:23 PM

    The drug will be manufactured at JB Pharma’s formulation manufacturing facility in Panoli, Gujarat

    Read More
  • JB Chemicals gets nod to set up wholly-owned step-down subsidiary in Philippines
    9th Aug 2023, 17:20 PM

    The Board of Directors of the company at its meeting held on August 9, 2023 has approved the same

    Read More
  • JB Chem & Pharma - Quarterly Results
    9th Aug 2023, 15:43 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.